Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study

Annals of Oncology

Volumn 9, Issue 9, 1998, Pages 1035-1037

  Mani, S ^a,c,d   Kugler, J W ^d,e,f   Sciortino, D F ^d,e,f   Garcia, J C ^d,e,f   Ansari, R H ^d,e,f   Humerickhouse, R ^a   Michelassi, F ^b,c   Posner, M C ^b   Shulman, K L ^a   Schilsky, R L ^a,b,c   List, M ^a,c   Vokes, E E ^a,c   Benner, S ^g  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c University of Chicago   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Oncology/Hematology Associates   (United States)

^f Michiana Hematology/Oncology   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ftorafur; Leucovorin; Pancreatic cancer; Uracil

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; UFT;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; MALE; ORAL DRUG ADMINISTRATION; PAIN; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANOREXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUCOVORIN; MALE; NAUSEA; PANCREATIC NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 7844236416     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008427231049     Document Type: Article

References (13)

1. Burris H, Moore MJ. Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with Advanced Pancreatic Cancer: A randomized trial. J Clin Oncol 1995; 14: 199.
2. Crown J, Casper ES, Botet J et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 8: 1682 6.
3. Maehara Y, Kakeji Y, Ohno S et al. Scientific basis for the combination of Tegafur with Uracil. Oncology 1997; 11 (9. Suppl 10): 14-6.
4. Pazdur R. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Oncology 1997; 11 (9, Suppl 10): 35-8.
5. Taguchi T, Furue H. Koyarma Y et al. Phase I study of UFT. Jpn J Cancer Chemother 1980; 7: 966-72.
6. Nakajima O, Ihara K, Isoda T et al. Phase I and II studies on mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Jpn J Cancer Chemother 1980; 7: 1558-68.
7. Taguchi T. Experience with UFT in Japan. Oncology 1997; 11 (9, Suppl 10): 30-5.
8. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333-8.
9. Mani S. An ongoing phase II study of UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas. Oncol 1997; 11 (9, Suppl 10): 124-8.
10. Sato Y, Sakai T, Okada T et al. A case of unresectable pancreatic cancer that responded to UFT chemotherapy. Gan-No-Rinsho 1990;36 (11): 2073-8.
11. Yamamoto M, Saitoh Y, Ohyanagi H et al. Clinical study on the effect of chemotherapy in the treatment of pancreatic cancer. Gan-to-Kagaku-Ryoho 1988; 15: 703-7.
12. Ohashi O, Yamamoto M, Ishida H et al. Retrospective analysis of postoperative chemotherapy with UFT against pancreatic cancer Gan To Kagaku Ryoho 1995; 22: 933-93.
13. Pazdur R, Lassere Y, Rhodes Vet al. Phase II trial of uracil and legafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296-300.